Angle’s H117 business update revealed that R&D activities are progressing well, while the company booked further research use sales. The first prospective clinical studies with Angle’s liquid biopsy system Parsortix in ovarian cancer reported positive early evaluation results and are due to report headline data in Q217. Our SOTP-based valuation is increased modestly to £140.3m or 188p/share. The main 2017 catalysts are the results from the ovarian cancer studies; an acce
14 Feb 2017
Data from ovarian cancer studies in Q217
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Data from ovarian cancer studies in Q217
ANGLE plc (AGL:LON) | 12.0 0 2.1% | Mkt Cap: 31.3m
- Published:
14 Feb 2017 -
Author:
Dr Jonas Peciulis -
Pages:
15
Angle’s H117 business update revealed that R&D activities are progressing well, while the company booked further research use sales. The first prospective clinical studies with Angle’s liquid biopsy system Parsortix in ovarian cancer reported positive early evaluation results and are due to report headline data in Q217. Our SOTP-based valuation is increased modestly to £140.3m or 188p/share. The main 2017 catalysts are the results from the ovarian cancer studies; an acce